Saturday, September 21, 2013 10:05:52 AM
So what if K really succeeds over time and becomes a global game changer in the treatment of cancer... then what kind of valuation might we anticipate...
The global cancer market has been estimated to be about 260 billion... I provided a link for this source in a post about a week ago... we know that approximately 50% of all cancers involve p53 mutation... which would make K's potential global market roughly 130 billion...
Since we are playing with numbers let's run two scenarios... the first assumes K captures 10 billion of the potential market share (this number is taken from an excellent SA article on P53 posted early this year following the NYTimes article), the second will assume 10% of global market share or 13 billion... including both stand alone and adjuvant possibilities... I don't really know what K's market share might be globally for cancer... others might be able to help us here... I am just playing with numbers... at this point CTIX would be a grown up company with a global reach and much higher expenses, much different economies of scale, marketing needs and so on... I am going to use Celgene's 2012 numbers as reported in yahoo to guide us here... Celgene showed 26.44% net profit on its gross revenue for 2012... I will use 25%...
10 billion $ scenario -
10 billion in gross rev
25% profit = 2.5 billion
P/E ratio of 20 = 50 billion market cap
150 million fully diluted = pps of $333.33
10% scenario -
13 billion in gross rev
25% profit = 3.25 billion
P/E ratio of 20 = 65 billion market cap
150 million fully diluted = pps of $433.33
What is K worth? This math suggests that K as a global indication for cancer could be worth $300 to $400 per share... as always...jmo...
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM